Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 2:37 p.m.

    📋 TCR2 THERAPEUTICS INC. (TCRR) - Financial Results

    Filing Date: 2022-05-12

    Accepted: 2022-05-12 07:02:07

    Event Type: Financial Results

    Event Details:

    Tcr2 Therapeutics Inc (the company was acquired by Adaptimmune Therapeutics plc (NASDAQ: ADAP)) (TCRR) Reports Q2 2022 Financial Results Tcr2 Therapeutics Inc (the company was acquired by Adaptimmune Therapeutics plc (NASDAQ: ADAP)) (TCRR) announced its financial results for the period ending Q2 2022. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 75275
      • TCR2 initiated the Phase 2 expansion portion of the ongoing Phase 1/2 clinical trial of gavo
      • T cell targeting mesothelin
      • expressing solid tumors. Enrollment is ongoing and the Company expects to report on progress from the Phase 2 portion of the clinical trial in the second half of
        • targeting CD70 with enhancements and allogeneic strategies.” Recent Developments Gavo-cel: •TCR2 initiated the Phase 2 expansion portion of the ongoing Phase 1/2 clinical trial of gavo-cel, its first-in-class TRuC-T cell targeting mesothelin-expressing solid tumors. Enrollment is ongoing and the Company expects to report on progress from the Phase 2 portion of the clinical trial in the second half of 2022
        • targeting TRuC-T cell program, in 2022
        • targeting mesothelin that co-expresses a PD-1:CD28 chimeric switch receptor. The Phase 1/2 clinical trial is evaluating the safety and efficacy of TC-510 in patients with mesothelin-expressing MPM, ovarian cancer, pancreatic cancer, colorectal cancer and triple negative breast cancer. The Company expects to report on progress from the Phase 1 portion of the clinical trial in the second half of 2022

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 15.12K 10.53K $4.58K +43.49%
    Current Assets Property Equipment Net 18.77K 17.07K $1.69K +9.91%
    Liabilities And Stockholders Equity Accounts Payable 4.48K 2.14K $2.34K +109.05%
    Liabilities And Stockholders Equity Operating Lease Liabilities 16.93K 3.37K $13.57K +402.91%
    Operating Expenses Loss From Operations 29.20K 21.59K $7.61K +35.25%
    Operating Expenses Net Loss 29.12K 21.51K $7.61K +35.38%
    Operating Activities Net Loss 29.12K 21.51K $7.61K +35.38%
    Changes In Operating Assets And Liabilities Prepaid Expenses Other Current Assets 4.40K 2.27K $2.13K +94.26%
    Changes In Operating Assets And Liabilities Accounts Payable 1.76K 1.68K $72.00 +4.28%
    Prepaid Expenses and Other Current Assets 15.12K 10.53K $4.58K +43.49%
    Property and Equipment, Net 18.77K 17.07K $1.69K +9.91%
    Other Assets 791.00 730.00 $61.00 +8.36%
    Accounts Payable 4.48K 2.14K $2.34K +109.05%
    Operating Lease Liabilities 16.93K 3.37K $13.57K +402.91%
    Loss from Operations 29.20K 29.20K $0.00 +0.00%
    Interest Income 117.00 117.00 $0.00 +0.00%
    Net Loss 29.12K 29.12K $0.00 +0.00%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Tcr2 Therapeutics Inc (the company was acquired by Adaptimmune Therapeutics plc (NASDAQ: ADAP))
    • CIK: 0001750019
    • Ticker Symbol: TCRR
    • Period End Date: 2022-05-12
    • Document Type: 8-K

Search

News categories